A Phase 4, Open-label, Single-Arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
Phase of Trial: Phase IV
Latest Information Update: 19 Jul 2018
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Anaplastic large cell lymphoma
- Focus Therapeutic Use
- Sponsors Takeda Oncology
- 11 Jul 2018 Planned primary completion date changed from 1 Oct 2015 to 30 Oct 2019.
- 11 Jul 2018 Status changed from active, no longer recruiting to recruiting.
- 20 Jul 2017 Planned End Date changed from 1 Apr 2020 to 23 Apr 2020.